The Europe pulmonary arterial hypertension market is expected to grow from US$ 1,959.47 million in 2022 to US$ 2,683.07 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028.
Growing Incidence of Pulmonary Arterial Hypertension Drives Europe Pulmonary Arterial Hypertension Market
Pulmonary arterial hypertension (PAH) affects the tiny arteries in the lung, making it thick and narrow and blocking the blood flow through the lungs. As a result, blood pressure in the lungs increases, and the heart faces difficulties in pumping blood through narrowed arteries. Over time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women between the ages of 30 and 60. Further, according to an article in European Respiratory Review published in 2019, the incidence of PAH is 7.6 cases per million in Scotland. Idiopathic PAH; in which a family history or an identified risk factor is present; is even rare, recording 2.6 cases per million in Scotland. Thus, the growing incidence of pulmonary arterial hypertension is driving the growth of the Europe pulmonary arterial hypertension market.Europe Pulmonary Arterial Hypertension Market Overview
The Europe pulmonary arterial hypertension market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the global pulmonary arterial hypertension market. The Europe pulmonary arterial hypertension market is expected to witness significant growth during the forecast period due to a rise in product approvals. Pulmonary hypertension is a rare condition that affects approximately one in 20,000 people in the UK. In 2021, 7,876 individuals in the UK suffered from pulmonary hypertension. In the UK, younger patients suffering from idiopathic pulmonary arterial hypertension (IPAH) have a 5-year survival above 80%. In the UK, patients suffering from PAH and CTEPH (the disease is caused due to a direct consequence of changes in the pulmonary vasculature) are most commonly treated in nine specialist centers across the country. The Pulmonary Hypertension Association UK (PHA-UK) in the UK advocates exclusively for people affected by pulmonary hypertension. Therefore, such initiatives are expected to fuel the pulmonary arterial hypertension drug market in the country during the forecast period.Europe Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)
Europe Pulmonary Arterial Hypertension Market Segmentation
The Europe pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.- Based on drugs, the Europe pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Europe pulmonary arterial hypertension market.
- Based on type, the Europe pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Europe pulmonary arterial hypertension market.
- Based on route of administration, the Europe pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Europe pulmonary arterial hypertension market.
- Based on distribution channel, the Europe pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Europe pulmonary arterial hypertension market.
- Based on country, the Europe pulmonary arterial hypertension market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2022, the UK registered the largest share in the Europe pulmonary arterial hypertension market.
Table of Contents
1. Introduction1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Pulmonary Arterial Hypertension Market - By Drugs
1.3.2 Europe Pulmonary Arterial Hypertension Market - By Type
1.3.3 Europe Pulmonary Arterial Hypertension Market - By Route of Administration
1.3.4 Europe Pulmonary Arterial Hypertension Market - By Distribution Channel
1.3.5 Europe Pulmonary Arterial Hypertension Market - By Country
2. Europe Pulmonary Arterial Hypertension Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pulmonary Arterial Hypertension Market - Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Pulmonary Arterial Hypertension Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
5.2 Market Restraints
5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
5.3 Market Opportunities
5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
5.4 Future Trend
5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
5.5 Impact analysis
6. Pulmonary Arterial Hypertension Market - Europe Analysis
6.1 Europe Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis
7. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs
7.1 Overview
7.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
7.3 Endothelin Receptor Antagonists (ERAs)
7.3.1 Overview
7.3.2 Endothelin Receptor Antagonists (ERAs): Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Prostacyclin and Prostacyclin Analogs
7.4.1 Overview
7.4.2 Prostacyclin and Prostacyclin Analogs: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.5 SGC Stimulators
7.5.1 Overview
7.5.2 sGC Stimulators: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Pde-5 Dipsticks
7.6.1 Overview
7.6.2 Pde-5 Dipsticks: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
8. Europe Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type
8.1 Overview
8.2 Europe Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
8.3 Branded
8.3.1 Overview
8.3.2 Branded: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Generics
8.4.1 Overview
8.4.2 Generics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration
9.1 Overview
9.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
9.3 Oral
9.3.1 Overview
9.3.2 Oral: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.4 Intravenous/ Subcutaneous
9.4.1 Overview
9.4.2 Intravenous/ Subcutaneous: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.5 Inhalational
9.5.1 Overview
9.5.2 Inhalational: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel
10.1 Overview
10.2 Europe Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
10.3 Hospital Pharmacies and Clinics
10.3.1 Overview
10.3.2 Hospital Pharmacies and Clinics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Online Pharmacies
10.4.1 Overview
10.4.2 Online Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.5 Retail Pharmacies
10.5.1 Overview
10.5.2 Retail Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Country Analysis
11.1 Europe: Pulmonary Arterial Hypertension Market
11.1.1 Overview
11.1.2 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
11.1.2.1 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.1.1 Overview
11.1.2.1.2 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.2.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.2.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.2.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.2.1 Overview
11.1.2.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.2.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.2.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.2.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.2.3 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.3.1 Overview
11.1.2.3.2 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.2.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.2.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.2.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.2.4 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.4.1 Overview
11.1.2.4.2 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.2.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.2.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.2.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.2.5 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.5.1 Overview
11.1.2.5.2 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.2.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.2.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.2.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.1.2.6 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.6.1 Overview
11.1.2.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
11.1.2.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
11.1.2.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.2.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
12. Pulmonary Arterial Hypertension Market - Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Johnson & Johnson
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Gilead Sciences Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 United Therapeutics Corp
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bayer AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Novartis AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 GSK Plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Teva Pharmaceutical Industries Ltd
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Lupin Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Pfizer Inc
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms
List of Tables
Table 1 Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 2. UK Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 3. UK Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 4. UK Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 5. UK Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 6. Germany Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 7. Germany Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 8. Germany Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 9. Germany Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 10. France Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 11. France Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 12. France Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 13. France Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 14. Italy Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 15. Italy Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 16. Italy Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 17. Italy Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 18. Spain Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 19. Spain Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 20. Spain Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 21. Spain Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 24. Rest of Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 25. Rest of Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 26. Organic Developments in the Europe pulmonary arterial hypertension market
Table 27. Inorganic Developments in the Europe pulmonary arterial hypertension market
Table 28. Glossary of Terms
List of Figures
Figure 1. Europe Pulmonary Arterial Hypertension Market Segmentation
Figure 2. Europe Pulmonary Arterial Hypertension Market - By Country
Figure 3. Europe Pulmonary Arterial Hypertension Market Overview
Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of the Europe Pulmonary Arterial Hypertension Market
Figure 5. UK to Show Significant Growth During Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Europe Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
Figure 9. Europe Pulmonary Arterial Hypertension Market- Revenue Forecast and Analysis - 2020 - 2028
Figure 10. Europe Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
Figure 11. Endothelin Receptor Antagonists (ERAs): Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 12. Prostacyclin and Prostacyclin Analogs: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 13. sGC Stimulators: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 14. Pde-5 Dipsticks: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 15. Europe Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
Figure 16. Branded: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 17. Generics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 18. Europe Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
Figure 19. Oral: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 20. Intravenous/ Subcutaneous: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Inhalational: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. Europe Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
Figure 23. Hospital Pharmacies and Clinics: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. Online Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. Retail Pharmacies: Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Europe: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 27. Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 28. UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Gilead Sciences Inc
- GSK Plc
- Johnson & Johnson
- Lupin Ltd
- Novartis AG
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
- United Therapeutics Corp
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 148 |
| Published | February 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 1959.47 Million |
| Forecasted Market Value ( USD | $ 2683.07 Million |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Europe |
